A systems approach to combat the significant antibiotic resistance challenge: Novel therapeutic strategies, mechanistic discoveries, and drug development

应对重大抗生素耐药性挑战的系统方法：新颖的治疗策略、机制发现和药物开发

• 批准号: nhmrc : GNT1157909
• 负责人: Prof Jian Li
• 金额: $ 78.54万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/systems-approach-combat-drug-development/1349246
• 关键词: systems; approach; combat; significant; antibiotic

Antibiotic-resistant ‘superbugs’ are a significant global medical challenge. Polymyxins are the only effective antibiotics against Gram-negative bacteria, although limited pharmacological data are available for their optimal use. In the next 5 years, I will re-develop polymyxins and discover novel antibiotics against high-priority pathogens. My research targets the “Bad Bugs, No Drugs” unmet medical need highlighted by the World Health Organization and The Infectious Diseases Society of America.

抗生素耐药性“超级细菌”是一个重大的全球医学挑战。多粘菌素是唯一有效的抗生素对革兰氏阴性菌，虽然有限的药理学数据可用于其最佳使用。在接下来的5年里，我将重新开发多粘菌素，并发现针对高优先级病原体的新型抗生素。我的研究目标是世界卫生组织和美国传染病协会强调的“坏虫子，没有药物”未满足的医疗需求。